• EMAIL
  • PRINT
  • PDF
  • Bookmark and Share

Education

  • LL.M. in Taxation, Boston University School of Law, 1992
  • J.D., Cornell University Law School, 1985
  • Th.M., Harvard University, cum laude, 1982
  • M.Div., Harvard University, 1977
  • B.A., Wesleyan University, cum laude, 1973

Bar Admissions

  • Massachusetts

Court Admissions

  • U.S. District Court, District of Massachusetts

Memberships & Affiliations

Board of Directors, Hereditary Disease Foundation, 2007-present

Member, New England-Canada Business Council

Board of Trustees and former President, Massachusetts Congregational Fund, a professionally managed $30,000,000 fund of church endowments, 1993-present

Board of Directors, American Congregational Association, 2005-present

Member, American, Massachusetts and Boston Bar Associations

Co-Chair, Corporate Law Committee, Boston Bar Association, 1999-2003

Law360’s Securities Editorial Advisory Board, 2013

DISTINCTIONS

Listed, Chambers & Partners USA Guide, an annual listing of the leading business lawyers and law firms in the world, 2008 and 2009 editions

Ranked AV® Preeminent™ 5.0 out of 5*

*AV® Preeminent ™ and BV® Distinguished™ are certification marks of Reed Elsevier Properties Inc., used in accordance with the Martindale-Hubbell certification procedures, standards and policies

Jonathan Guest

  • |
Partner
  • T: 617.449.6598
    F: 617.607.9348

Representative Matters

$120 million registered cross-border universal shelf offering by Canadian natural resource company operating in China (NYSE and TSX).
$500 million Rule 144A offering by U.K.-based investment fund focused on ownership and development of Ukraine commercial and residential properties with shares to be listed on NYSE Euronext (adverse market conditions prevented completion).
€300 million global IPO and Rule 144A offering by U.K.-based owner of German commercial properties and listing on the AIM of the London Stock Exchange.
€400 million global IPO and Rule 144A offering by U.K.-based owner of German retail properties and listing on the AIM of the London Stock Exchange, and €270 million global and Rule 144A follow-on offering.
$300 million cross-border PIPE followed by two $100 million private placements by a Canadian natural resource company (TSX and NYSE).
$45 million aggregate financing (public and private offerings) of U.S. public drug development company.
$40 million cross-border "bought deal" offering by Canadian natural resource company (TSX).
$41 million aggregate PIPEs of common stock, debentures and warrants for drug development company (AMEX).
$60 million cross-border "bought deal" offering of common shares by Canadian natural resource company (TSX and AMEX).
$100 million cross-border public offering by Canadian natural resource company (TSX and AMEX).
$30 million aggregate rounds of preferred stock, subordinated notes and senior credit financing to private international proprietary battery production company.
NYSE and AMEX listing of U.S. and foreign companies.
Unsolicited tender offer by Canadian natural resources company (NYSE) for U.S. target company.
$1 billion acquisition of Canadian natural resources company (TSX and AMEX) by U.S. based Company (TSX and NYSE).
$35 million sale of inventory by Australian company to U.S. public company (NYSE) for stock consideration.
$70 million acquisition by public company (Nasdaq) of private company engaged in production and internet delivery of images to design professionals.
$30 million acquisition of offshore properties for cash and stock of U.S. oil and gas exploration and production company.
$27 million sale of Finnish telecommunications company stock to U.S. acquirer.
$12 million sale of assets of international wholesale distributor of consumer electronics to U.S. retail company.
Reverse merger of private drug development company into public "shell" company.